SERHealthcare · Biotechnology

SER Stock Forecast: Serina Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026

$2.04

+4.08% on the day

The 2 Wall Street analysts covering Serina Therapeutics, Inc. hold a median 12-month price target of $9.5 — +365.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 3 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$49.8M

Ticker Nerd rank

19 / 100

Median analyst target

$9.50

Analysts covering

Revenue$0.0

Operating income−$6.8M

Net income−$6.4M

Free cash flow−$6.7M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+1.5%

−25.3%

YTD

+6.6%

−61.0%

From 52W high

−63.8%

From 52W low

+59.4%

$1.28

$5.63

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

SER stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Serina Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026

19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Volatility

Accruals

Value

Momentum

Quality

Growth

Issuance

Size (82): Smaller than most of the companies we track.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SER stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SER, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts

2 Buy0 Hold0 Sell

Low $8.00Median $9.50High $11.00

The green dot is the last close — the median target sits +365.7% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
10 Sept 2026	BTIG	Reiterates	Buy	—
1 July 2026	BTIG	Initiates	Buy	—
28 Aug 2025	HC Wainwright & Co.	Reiterates	Buy	—
14 July 2025	HC Wainwright & Co.	Initiates	Buy	—
11 Mar 2025	Jones Trading	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SER appears on the weeks it earns a place.

Performance

SER vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, Serina Therapeutics, Inc. returned −61.0% against +16.2% for the S&P 500, dividends included.

SER vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SER analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Serina Therapeutics, Inc. (SER) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 1.6×
Price / sales: 328.8×
Price / book: 2.7×
EV / EBITDA: −1.2×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −207.9%
Return on assets: −92.3%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Serina Therapeutics, Inc. (SER) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Serina Therapeutics, Inc. has a market value of $49.8M and an enterprise value of $30.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$21.2M.
Free cash flow in the twelve months to 30 June 2026: −$21.2M.
Shares outstanding: 15.0M.
Trailing P/E: 1.6×; forward P/E: −1.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Serina Therapeutics, Inc. employs 16 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Oct 2026

Data provided by Twelve Data

Peers

SER vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
SERSerina Therapeutics, Inc.	$49.8M	19
DWTXDogwood Therapeutics, Inc.	$49.6M	38
ANVSAnnovis Bio, Inc.	$50.2M	27
ELTXElicio Therapeutics, Inc.	$50.5M	38
TILInstil Bio, Inc.	$49.0M	37
BSEMBioStem Technologies, Inc.	$48.7M	57
INMBINmune Bio, Inc.	$51.3M	53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Serina Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SER news & analysis

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress"

GlobeNewsWire · 23 Sept 2026positive

Serina Therapeutics announced that CEO Steven Ledger will present at Tribe Public's webinar and Q&A event on September 24, 2026, titled "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress." Registration for the event is now open.

Why it matters — Serina watchers would be interested because the event provides an opportunity to hear directly from the CEO about SER-252's clinical progress, a key pipeline program targeting a large Parkinson's disease patient population.

Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 10 Sept 2026neutral

Serina Therapeutics announced that CEO Steve Ledger will present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026 in New York. The company will also participate in one-on-one investor meetings during the conference.

Why it matters — The presentation provides an opportunity for the company to showcase its POZ Platform drug optimization technology to investors at a major industry conference.

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2

GlobeNewsWire · 9 Sept 2026positive

Serina Therapeutics announced that the independent Safety Monitoring Committee completed its blinded review of Cohort 1 in the Phase 1b registrational study of SER-252 for advanced Parkinson's disease and recommended advancing to Cohort 2. Pharmacokinetic observations at the lowest dose were consistent with sustained apomorphine exposure, and blinded Cohort 1 data showed sustained periods of motor function improvement in individual patients on exploratory measures. Topline data from the single-ascending-dose portion are expected in the first half of 2027.

Why it matters — This advancement to Cohort 2 and supportive early observations mark progress for SER-252, Serina's lead clinical-stage candidate for advanced Parkinson's disease.

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewsWire · 13 Aug 2026neutral

Serina Therapeutics reported its financial results for the second quarter ended June 30, 2026, and provided key business updates. The company is a clinical-stage biotechnology firm focused on its POZ Platform drug optimization technology.

Why it matters — The quarterly financial results and business updates offer a regular check on Serina's financial health and progress with its POZ Platform technology.

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

GlobeNewsWire · 24 July 2026neutral

Serina Therapeutics announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026.

Why it matters — Conference participation gives Serina an opportunity to present its POZ Platform drug optimization technology to the investment community.

FAQ

Frequently asked questions about SER stock

What is the SER stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Serina Therapeutics, Inc. have a median 12-month price target of $9.5, with estimates ranging from $8 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SER stock a buy right now?

Of the 2 analysts covering Serina Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Serina Therapeutics, Inc. 19 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SER?

As at 3 Oct 2026, Serina Therapeutics, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (82 of 100).

Will SER stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +365.7% from the last close, and Ticker Nerd's factor model ranks Serina Therapeutics, Inc. 19 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SER stock forecast for 2030?

No analyst covering Serina Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SER are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $11 over the next 12 months.

How has SER stock performed over the past year?

Serina Therapeutics, Inc. returned -61.0% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Serina Therapeutics, Inc. do?

Serina Therapeutics Inc. is a clinical-stage biotechnology company focused on developing polymer-enabled therapeutics for neurological diseases and other serious conditions.

What is the latest news on SER?

The most recent item we track (GlobeNewsWire, 23 Sept 2026): "Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress"". Serina Therapeutics announced that CEO Steven Ledger will present at Tribe Public's webinar and Q&A event on September 24, 2026, titled "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress." Registration for the event is now open.

Company

About Serina Therapeutics, Inc.

Serina Therapeutics Inc. is a clinical-stage biotechnology company focused on developing polymer-enabled therapeutics for neurological diseases and other serious conditions. The company’s core work centers on its proprietary POZ Platform, a drug-delivery technology designed to improve how medicines are loaded, released, and administered, with applications across small molecules, RNA-based therapies, and antibody-drug conjugates. Serina Therapeutics Inc. is advancing a pipeline of wholly owned product candidates aimed primarily at central nervous system disorders, including Parkinson’s disease, along with programs in pain and other therapeutic areas. Its current business is centered on research, preclinical development, and clinical evaluation of drug candidates built around its platform technology. Based in Huntsville, Alabama, Serina Therapeutics Inc. plays a specialized role in the biotechnology market by combining materials science with drug development to address treatment challenges in difficult-to-deliver therapies.

CEO Mr. Steven A. Ledger · 16 employees · United States · https://serinatherapeutics.com